Kyntra Bio Inc. has provided an update on its recent corporate activities and clinical development programs. The company completed the sale of FibroGen China to AstraZeneca for approximately $220 million and repaid its term loan to Morgan Stanley Tactical Value. These actions have extended the company’s cash runway into 2028. Kyntra Bio highlighted progress with its oncology pipeline, including the initiation of a Phase 2 trial for FG-3246, a CD46-targeting antibody-drug conjugate $(ADC)$, and FG-3180, a PET imaging agent, in metastatic castration-resistant prostate cancer (mCRPC). Interim results from this trial are expected in the second half of 2026. The presentation also noted the high unmet need for new treatment options in late-stage prostate cancer and described YS5FL, a fully-human monoclonal antibody targeting CD46, as part of its approach to developing more targeted therapies for mCRPC. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyntra Bio Inc. published the original content used to generate this news brief on January 20, 2026, and is solely responsible for the information contained therein.